• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌患者的部分肾切除术与根治性肾切除术:一项系统评价和荟萃分析

Partial Versus Radical Nephrectomy in Patients with Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

作者信息

Yang Yong

机构信息

Department of Urology, The Ninth Hospital of Xi'an, Xi'an, 710054, China.

出版信息

Urol J. 2020 Mar 16;17(2):109-117. doi: 10.22037/uj.v0i0.5358.

DOI:10.22037/uj.v0i0.5358
PMID:32180211
Abstract

PURPOSE

Radical nephrectomy (RN) and partial nephrectomy (PN) are widely used for early-stage renal cell carcinoma (RCC). However, the results were inconsistent while comparing the efficiency of RN and PN. This study aimed to assess the perioperative effectiveness of RN and PN for treating RCC.

MATERIAL AND METHODS

PubMed, Embase, and the Cochrane Library electronic database were searched for studies on adults with RCC comparing RN and PN published until September 2019. The perioperative efficacy and safety outcomes were calculated using odds ratio (OR) and standard mean difference (SMD) with 95% confidence intervals (CIs) for dichotomous and continuous data, respectively. Subgroup analysis were conducted based on tumor stage and surgery methods for evaluation of the treatment effect on specific subsets.

RESULTS

A total of 23 studies involving 30,018 patients with RCC were included in this meta-analysis. Notably, RCC treated with PN was associated with low incidences of hospital mortality (OR: 0.58; 95% CI: 0.38-0.89; P = 0.013) and reoperation rate (OR: 0.74; 95% CI: 0.58-0.95; P = 0.016) as compared to RN. However, PN was associated with an increased risk of overall postoperative complications (OR: 1.40; 95% CI: 1.17-1.68, P < 0.001), postoperative hemorrhagic complications (OR: 1.92; 95% CI: 1.28-2.87, P = 0.002), and urinary fistula (OR: 17.65; 95% CI: 5.35-58.30, P < 0.001) as compared to RN.

CONCLUSION

These findings suggested that PN was associated with lower incidences of hospital mortality and reoperation rate, whereas RN was associated with fewer complications.

摘要

目的

根治性肾切除术(RN)和部分肾切除术(PN)广泛应用于早期肾细胞癌(RCC)。然而,比较RN和PN疗效的结果并不一致。本研究旨在评估RN和PN治疗RCC的围手术期有效性。

材料与方法

检索PubMed、Embase和Cochrane图书馆电子数据库,查找截至2019年9月发表的比较RN和PN治疗成人RCC的研究。分别采用比值比(OR)和标准均差(SMD)及95%置信区间(CI)计算二分法和连续数据的围手术期疗效和安全性结果。基于肿瘤分期和手术方法进行亚组分析,以评估对特定亚组的治疗效果。

结果

本荟萃分析共纳入23项研究,涉及30018例RCC患者。值得注意的是,与RN相比,PN治疗的RCC患者医院死亡率(OR:0.58;95%CI:0.38 - 0.89;P = 0.013)和再次手术率(OR:0.74;95%CI:0.58 - 0.95;P = 0.016)较低。然而,与RN相比,PN术后总体并发症(OR:1.40;95%CI:1.17 - 1.68,P < 0.001)、术后出血并发症(OR:1.92;95%CI:1.28 - 2.87,P = 0.002)和尿瘘(OR:17.65;95%CI:5.35 - 58.30,P < 0.001)的风险增加。

结论

这些发现表明,PN与较低的医院死亡率和再次手术率相关,而RN与较少的并发症相关。

相似文献

1
Partial Versus Radical Nephrectomy in Patients with Renal Cell Carcinoma: A Systematic Review and Meta-analysis.肾细胞癌患者的部分肾切除术与根治性肾切除术:一项系统评价和荟萃分析
Urol J. 2020 Mar 16;17(2):109-117. doi: 10.22037/uj.v0i0.5358.
2
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.部分肾切除术与根治性肾切除术治疗 T1b 和 T2 期临床肾肿瘤的比较:系统评价和荟萃分析。
Eur Urol. 2017 Apr;71(4):606-617. doi: 10.1016/j.eururo.2016.08.060. Epub 2016 Sep 7.
3
A comparison of overall survival and perioperative outcomes between partial and radical nephrectomy for cT1b and cT2 renal cell carcinoma-Analysis of a national cancer registry.cT1b和cT2期肾细胞癌行部分肾切除术与根治性肾切除术的总生存率及围手术期结局比较——一项国家癌症登记分析
Urol Oncol. 2018 Mar;36(3):90.e9-90.e14. doi: 10.1016/j.urolonc.2017.11.008. Epub 2017 Dec 16.
4
Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis.经皮消融与部分和根治性肾切除术治疗 T1a 期肾癌:基于人群的分析。
Ann Intern Med. 2018 Jul 17;169(2):69-77. doi: 10.7326/M17-0585. Epub 2018 Jun 26.
5
Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma.根治性肾切除术与部分肾切除术治疗 cT1 期肾癌。
Eur Urol. 2018 Dec;74(6):825-832. doi: 10.1016/j.eururo.2018.08.028. Epub 2018 Sep 24.
6
Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.cT1-2/N0/M0期透明细胞肾细胞癌行微创部分肾切除术与微创根治性肾切除术的肿瘤学结局:一项倾向评分匹配分析
World J Urol. 2017 May;35(5):789-794. doi: 10.1007/s00345-016-1923-2. Epub 2016 Aug 30.
7
Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.部分肾切除术与根治性肾切除术相比,在老年 Ib-II 期肾肿块患者中并不具有总体生存优势:国家癌症数据库分析。
Cancer. 2018 Oct 1;124(19):3839-3848. doi: 10.1002/cncr.31582. Epub 2018 Sep 12.
8
Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.美国 T1bN0M0 期肾细胞癌(RCC)采用部分肾切除术和根治性肾切除术治疗后的生存:倾向评分法。
BJU Int. 2012 May;109(10):1457-62. doi: 10.1111/j.1464-410X.2011.10597.x. Epub 2011 Sep 20.
9
Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery.比较行经皮微波消融术与手术治疗临床 T1b 期肾细胞癌患者的结局。
Urology. 2020 Jan;135:88-94. doi: 10.1016/j.urology.2019.09.024. Epub 2019 Oct 1.
10
Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a systematic review and meta-analysis.经腹腔与经腹膜后腹腔镜肾切除术治疗肾细胞癌的比较:系统评价和荟萃分析。
BJU Int. 2013 Apr;111(4):611-21. doi: 10.1111/j.1464-410X.2012.11598.x. Epub 2012 Oct 29.

引用本文的文献

1
Renal cell cancer treatment: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) surgery-focused consensus update.肾细胞癌治疗:拉丁美洲肿瘤协作组(LACOG)和拉丁美洲肾癌组(LARCG)以手术为重点的共识更新
Ther Adv Urol. 2025 Apr 14;17:17562872241312581. doi: 10.1177/17562872241312581. eCollection 2025 Jan-Dec.
2
Rare Renal Malignancies: A Case Series Highlighting Uncommon Presentations and Their Management Strategies.罕见肾恶性肿瘤:病例系列研究凸显罕见表现及其管理策略
Cureus. 2024 Dec 4;16(12):e75119. doi: 10.7759/cureus.75119. eCollection 2024 Dec.
3
The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma.
透明细胞肾细胞癌的诊断与治疗现状
Cancers (Basel). 2024 Dec 1;16(23):4034. doi: 10.3390/cancers16234034.
4
The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs.PRO-RCC 研究:荷兰一项长期的前列腺癌患者预后前瞻性队列研究,为“队列内试验”设计提供基础设施。
BMC Cancer. 2023 Jul 11;23(1):648. doi: 10.1186/s12885-023-11094-9.
5
A Japanese registry study and systematic review of particle therapy for renal cell carcinoma.一项针对肾细胞癌的粒子治疗的日本注册研究和系统评价。
J Radiat Res. 2023 Jun 16;64(Supplement_1):i41-i48. doi: 10.1093/jrr/rrad010.
6
NUDT1 Could Be a Prognostic Biomarker and Correlated with Immune Infiltration in Clear Cell Renal Cell Carcinoma.NUDT1可能是一种预后生物标志物,且与透明细胞肾细胞癌中的免疫浸润相关。
Appl Bionics Biomech. 2022 Dec 26;2022:3669296. doi: 10.1155/2022/3669296. eCollection 2022.
7
Partial Nephrectomy Versus Radical Nephrectomy for Endophytic Renal Tumors: Comparison of Operative, Functional, and Oncological Outcomes by Propensity Score Matching Analysis.肾内生性肿瘤行部分肾切除术与根治性肾切除术的比较:倾向评分匹配分析对手术、功能及肿瘤学结局的比较
Front Oncol. 2022 Jul 26;12:916018. doi: 10.3389/fonc.2022.916018. eCollection 2022.
8
Long Noncoding RNA Small Nucleolar Host Gene: A Potential Therapeutic Target in Urological Cancers.长链非编码RNA小核仁宿主基因:泌尿系统癌症中的潜在治疗靶点
Front Oncol. 2021 Apr 22;11:638721. doi: 10.3389/fonc.2021.638721. eCollection 2021.
9
The diagnostic utility of diffusion weighted MRI imaging and ADC ratio to distinguish benign from malignant renal masses: sorting the kittens from the tigers.弥散加权 MRI 成像和 ADC 比值对鉴别良恶性肾肿块的诊断效用:从虎群中分辨出小猫。
BMC Urol. 2021 Apr 22;21(1):67. doi: 10.1186/s12894-021-00832-5.
10
Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review.肾细胞癌患儿的特征与转归:一项叙述性综述
Cancers (Basel). 2020 Jul 3;12(7):1776. doi: 10.3390/cancers12071776.